Orally Disintegrating Tablet Market Report 2026

The orally disintegrating tablet market size has grown strongly in recent years. It will grow from $16.2 billion in 2025 to $17.62 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to limited awareness of orally disintegrating tablets, conventional tablet dominance, low pediatric and geriatric targeting, reliance on hospital pharmacy channels, slow adoption of specialty drug formulations.

The orally disintegrating tablet market size is expected to see strong growth in the next few years. It will grow to $24.43 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to technological advancements in odt formulation, increasing patient preference for convenience and compliance, growth of online and retail pharmacy networks, rising prevalence of cns and gastrointestinal disorders, expanding r&d in anti-psychotics and anti-epileptics. Major trends in the forecast period include rising demand for easy-to-swallow and patient-friendly dosage forms, expansion of pediatric and geriatric patient targeting, growth in hospital and retail pharmacy distribution channels, increased focus on rapid-onset therapeutics, rising adoption of specialty drug classes in odt formulations.

The rising incidence of neurological disorders is expected to drive growth in the orally disintegrating tablet market in the coming years. Neurological disorders are conditions that affect the nervous system, including the brain and peripheral nerves, disrupting normal neural functions. The increasing prevalence of these disorders is primarily due to longer life expectancy, as age-related conditions like Alzheimer’s and Parkinson’s disease become more common, resulting in a higher overall case load. Orally disintegrating tablets support neurological disorders by enabling easier and faster medication administration, especially for patients with swallowing difficulties (dysphagia) or cognitive impairments. This improves treatment adherence, ensures timely dosing, and enhances therapeutic effectiveness. For example, in March 2023, the Alzheimer’s Association, a U.S.-based nonprofit, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia, with projections indicating an increase to 13.8 million by 2060. Therefore, the growing incidence of neurological disorders is driving the orally disintegrating tablet market.

Key companies in the orally disintegrating tablet market are focusing on innovative drug formulations, such as patient-centric delivery systems, to enhance adherence and improve outcomes. A patient-centric drug delivery system is designed to make medication easier and more comfortable to take, enhancing the overall treatment experience. For instance, in May 2025, Viatris Inc., a U.S.-based healthcare company, launched Gen-Clozapine orally disintegrating tablets (ODT) in Canada for treatment-resistant schizophrenia. As the first clozapine ODT available in the country, it disintegrates quickly in the mouth without water, supporting patients with swallowing or adherence challenges. The product is offered in multiple strengths (12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg), enabling precise dose titration aligned with established treatment protocols.

In December 2024, Novo Holdings A/S, a Denmark-based life sciences investment firm, acquired Catalent, Inc. for $16.5 billion. This acquisition strengthens Novo Holdings’ presence in contract development and manufacturing by partnering with a global leader in drug delivery and fill-finish services. Catalent, Inc., a U.S.-based CDMO, specializes in advanced drug-delivery technologies, including orally disintegrating tablets, softgels, and biologics fill-finish solutions.

Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.

North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the orally disintegrating tablet market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the orally disintegrating tablet market by increasing the cost of imported active pharmaceutical ingredients (APIs) and excipients used in ODT production. Segments such as anti-psychotics, anti-epileptics, and central nervous system stimulants are particularly impacted, with regions including Asia-Pacific and Europe facing higher import duties. While tariffs have led to increased production costs and potential price adjustments, they also encourage domestic sourcing, local manufacturing expansion, and innovation in cost-effective formulations.

The orally disintegrating tablet market research report is one of a series of new reports that provides orally disintegrating tablet market statistics, including orally disintegrating tablet industry global market size, regional shares, competitors with a orally disintegrating tablet market share, detailed orally disintegrating tablet market segments, market trends and opportunities, and any further data you may need to thrive in the orally disintegrating tablet industry. This orally disintegrating tablet market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An orally disintegrating tablet (ODT) is a type of tablet designed to rapidly dissolve or break down in the mouth without the need for water. It is especially beneficial for patients who have difficulty swallowing, providing a convenient and easy-to-administer alternative to conventional tablets.

The main drug classes of orally disintegrating tablets include antipsychotics, antiepileptics, central nervous system stimulants, anxiolytics, anti-Parkinsonian drugs, antihypertensives, nonsteroidal anti-inflammatory drugs, antiallergy drugs, proton pump inhibitors, and others. Antipsychotics, for example, are used to treat mental health conditions by reducing symptoms such as hallucinations and delusions. These tablets are indicated for multiple conditions, including central nervous system disorders, gastrointestinal diseases, cardiovascular disorders, allergies, and more. They are distributed through hospital pharmacies, online pharmacies, retail pharmacies, and drugstores, and are used by various patient groups, including pediatric, adult, and geriatric populations.

The orally disintegrating tablet market consists of sales of benadryl orally disintegrating tablets (diphenhydramine), zofran orally disintegrating tablets (ondansetron), cialis orally disintegrating tablets (tadalafil), and lamictal orally disintegrating tablets (lamotrigine). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.